Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 2 of 120 for:    bone marrow biopsy OR bone marrow aspiration OR bone marrow exam | Open Studies | NIH, U.S. Fed

Stem Cell Therapy to Improve Burn Wound Healing

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University of Miami
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Dr. E.Badiavas, University of Miami
ClinicalTrials.gov Identifier:
NCT02104713
First received: April 1, 2014
Last updated: August 27, 2014
Last verified: August 2014
  Purpose

This study will determine the safety of allogeneic stem cell therapy from healthy donors, for 2nd degree burn wounds of less than 20% Total Body Surface Area (TBSA), at four different dose levels.

Clinical evaluation will take place at weekly intervals until wound closure and then monthly for a period of no less than 12 months.

Once the safety and dose-response analysis in Specific Aim 1 is completed, an expanded trial will be initiated to better examine the efficacy of MSC therapy in 2nd degree burn wounds. Specific Aim 1 will establish the maximum safe dose that will be used in this Phase II efficacy tria


Condition Intervention Phase
Skin Burn Degree Second
Procedure: Bone Marrow Aspiration from Healthy Donors
Biological: Allogeneic (MSC's) Application to the Burn Wounds
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Stem Cell Therapy to Improve Burn Wound Healing

Resource links provided by NLM:


Further study details as provided by University of Miami:

Primary Outcome Measures:
  • Reduction of number of Adverse Events [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
    Reduction of number of Adverse Events like blistering, inflammation and rash per participant


Estimated Enrollment: 20
Study Start Date: April 2014
Estimated Study Completion Date: February 2017
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Donors
Bone Marrow aspiration from healthy donors
Procedure: Bone Marrow Aspiration from Healthy Donors
Bone Marrow Aspiration from Healthy Donors
Experimental: Allogeneic (MSC's) Application to the Burn Wounds

Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose

  1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.
  2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.
  3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.
  4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.

Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart.

Biological: Allogeneic (MSC's) Application to the Burn Wounds

Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose

  1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.
  2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.
  3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.
  4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.

Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart.


  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

- Donors:

Eligibility Criteria:

  • No history of malignancy
  • No active coagulopathy and/or hypocoagulable state
  • No history of cardio/pulmonary conditions
  • Negative tests for Hepatitis A, Hepatitis B, Hepatitis C, RPR, HIV 1 / 2 HTLV I/II, Chagas Disease and WNV, HCV/HIV Nucleid Acid test.
  • Hemoglobin ≥ 13.0 g/dL
  • Platelet count 140,000 to 440,000/ul
  • WBC 3.0 to 11.0 K/ul
  • No anomalies on the CBC and differential suggestive of a hematopoietic disorder
  • Creatinine ≤ 1.5 mg/dL
  • ALT ≤ 112 IU/L
  • AST ≤ 100 IU/L
  • Bilirubin < 1.5 mg/dL
  • No diabetes
  • Systolic blood pressure ≤ 170
  • Diastolic blood pressure ≤ 90
  • No history of autoimmune disorders

Recipients:

Inclusion Criteria:

  1. Male or female subjects 18 years of age or older with Superficial, Intermediate or Deep 2nd Degree Burn Wounds
  2. Injury within the prior 7 days
  3. Subjects must understand and give written informed consent.
  4. Subjects must agree to have biopsies performed as per protocol
  5. Subjects must be accessible for weekly wound treatment and assessment visits
  6. Males and females must agree to use an acceptable method of contraception. Exceptions will be females of non-childbearing age and monogamous males who are partners of females of non-childbearing age. Acceptable methods of birth control include; history of sterilization, birth control pills, depoprogesterone injections, a barrier contraceptive such as a condom with or without spermicide cream or gel, diaphragms or cervical cap with or without spermicide create or gel, or an intrauterine device (IUD).
  7. Maximum wound size limited to:

    • Single wound: ≤ 5% body surface area (BSA)
    • Multiple wounds treated in a defined anatomical region with ≤ 20% cumulative BSA with individual wounds ≤ 5%
  8. Diabetic subjects: HbA1c ≤ 8%

Exclusion Criteria:

  1. Solely 1st degree or solely 3rd degree burns
  2. Subjects with superficial 2nd degree burn who are expected to heal within 2 weeks post standard therapy
  3. Evidence of active infection at the wound site
  4. Evidence of significant wound healing prior to treatment
  5. Wound located in the area of hands, feet, face, perineum, or across joints
  6. Electrical or chemical burns
  7. Have any requirement for the use of systemic steroids or immunosuppressive
  8. Subjects Allergic to human albumin, streptomycin, or penicillin
  9. Be a pregnant female or nursing mother
  10. Subjects who are known or found to be HIV positive
  11. History of alcohol or substance abuse within the past 18 months
  12. Patients with severe medical conditions

    1. Malignancy (other than non melanoma skin cancer) not in remission or in remission less than 5 years
    2. Life expectancy less than two years
    3. Severe cardiopulmonary disease restricting ambulation to the clinical facility
  13. WBC <3 or > 10 x109/L, Hgb < 9g/dL, platelets count 100x109/L or less, serum creatinine > 1.5 times the upper normal limit, AST or ALT > 2.5 times the upper normal limit.
  14. Subjects with abnormal bilirubin levels.
  15. Subjects with abnormal PT/INR laboratory values while not on chronic anticoagulant treatment which can be held for minor surgical procedures
  16. Those with a know history of coagulopathy
  17. Subjects who are potential recipients of tissue or organ transplantation
  18. Subjects with circulating Hepatitis B antigen and/or who are seropositive for Hepatitis C antibody
  19. History of poor compliance, unreliability
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02104713

Locations
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Olga Orozco, CCRC    305-585-8160    oorozco@med.miami.edu   
Principal Investigator: Carl I. Schulman, MD,PhD,MSPH,FACS         
Sub-Investigator: Louis R. Pizano, MD,MBA,FACS         
Sub-Investigator: Evangelos V. Badiavas, MD, PhD         
Sub-Investigator: Nicholas Namias, MD,MBA,FACS,FCCM         
Sponsors and Collaborators
Dr. E.Badiavas
Investigators
Principal Investigator: Carl Schulman, MD, PhD University of Miami
  More Information

No publications provided

Responsible Party: Dr. E.Badiavas, Associate Professor of Dermatology & Cutaneous Surgery, University of Miami
ClinicalTrials.gov Identifier: NCT02104713     History of Changes
Other Study ID Numbers: 20120925
Study First Received: April 1, 2014
Last Updated: August 27, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Miami:
Skin Burn Degree Second
Second degree Burn
Burn wound

Additional relevant MeSH terms:
Burns
Wounds and Injuries

ClinicalTrials.gov processed this record on November 20, 2014